Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones. Several analogues were later developed, some of which—such as pioglitazone and troglitazone—made it to the market.
Ciglitazone significantly decreases VEGF production by human granulosa cells in an in vitro study, and may potentially be used in ovarian hyperstimulation syndrome. Ciglitazone is a potent and selective PPARγ ligand. It binds to the PPARγ ligand-binding domain with an EC50 of 3.0 µM. Ciglitazone is active in vivo as an anti-hyperglycemic agent in the ob/ob murine model. Inhibits HUVEC differentiation and angiogenesis and also stimulates adipogenesis and decreases osteoblastogenesis in human mesenchymal stem cells.
^Willson, T.M.; Cobb, J.E.; Cowan, D.J.; et al. (1996). "The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones". J Med Chem39: 665–668. doi:10.1021/jm950395a.CS1 maint: Explicit use of et al. (link)
^Xin, X.; et al. (1999). "Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo;". J. Biol. Chem.274: 9116–21. doi:10.1074/jbc.274.13.9116. PMID10085162.CS1 maint: Explicit use of et al. (link)